Apogee Therapeutics (APGE) Accumulated Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Accumulated Expenses data on file, last reported at $28.6 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $28.6 million, up 7.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.6 million (up 7.68% YoY), and the FY2025 annual result was $23.2 million, down 4.43% from the prior year.
• Accumulated Expenses grew to $28.6 million in Q1 2026 per APGE's latest filing, from $23.2 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $29.6 million in Q3 2025 and troughed at $515000.0 in Q4 2022.
• A 5-year average of $17.1 million and a median of $21.8 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses soared 3261.94% in 2023, then dropped 4.43% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $515000.0 in 2022, then soared by 3261.94% to $17.3 million in 2023, then surged by 40.09% to $24.3 million in 2024, then dropped by 4.43% to $23.2 million in 2025, then climbed by 23.28% to $28.6 million in 2026.
• Business Quant data shows APGE's Accumulated Expenses at $28.6 million in Q1 2026, $23.2 million in Q4 2025, and $29.6 million in Q3 2025.